Phase I Study of Entinostat and Nivolumab with or without Ipilimumab in Advanced Solid Tumors (ETCTN-9844)
Evanthia T. Roussos Torres(University of Southern California), Roisín M. Connolly(Johns Hopkins University)
Cited by 35
Related Papers
Use of androgen deprivation therapy in prostate cancer: indications and prevalence
|Asian Journal of Andrology|2012|63
Entinostat, nivolumab and ipilimumab for women with advanced HER2-negative breast cancer: a phase Ib trial
|Nature Cancer|2024|46
A new Neu—a syngeneic model of spontaneously metastatic HER2-positive breast cancer
|Clinical & Experimental Metastasis|2024|6
A class act: HDAC1- <i>Malat1</i> regulates MDSC apoptosis and cell cycling to decrease suppression of T cells
|bioRxiv (Cold Spring Harbor Laboratory)|2026|1
Mimicking the breast metastatic microenvironment: characterization of a novel syngeneic model of HER2 <sup>+</sup> breast cancer
|bioRxiv (Cold Spring Harbor Laboratory)|2024|0